N-alpha-甲基苄基-1-氨基苯并三氮唑 | 105026-61-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 中文名称: N-alpha-甲基苄基-1-氨基苯并三氮唑
• 中文别名: ALPHA-甲基苄基氨基苯并噻唑
• 英文名称: alpha-Methylbenzylaminobenzotriazole
• 英文别名: N-(1-phenylethyl)benzotriazol-1-amine
• CAS: 105026-61-7
• 化学式: C₁₄H₁₄N₄
• 分子量: 238.29
• InChiKey: ZNKDFAUZPHKYJI-UHFFFAOYSA-N

物化性质

• 沸点：
  401.9±38.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3 (20 ºC 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  42.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• USE OF AMITIFADINE, (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN METHODS AND COMPOSITIONS WITH ENHANCED EFFICACY AND REDUCED METABOLIC SIDE EFFECTS AND TOXICITY FOR TREATMENT OF DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS
  申请人：McKinney Anthony Alexander

  公开号：US20160346249A1

  公开（公告）日：2016-12-01

  The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane compositions are metabolized by either or both MAO-A or cytochrome P450 enzymes and thus are effective in the treatment of individuals with cytochrome P450 polymorphisms or who are taking other medications that affect the cytochrome P450 pathway.

  本发明涉及（+）-1-（3,4-二氯苯基）-3-氮杂双环[3.1.0]己烷及其药用可接受的活性盐、多晶形态、糖基化衍生物、代谢物、溶剂合物、水合物和/或前药，以及其单独使用或与额外的精神疗法组合一起治疗受单胺神经递质影响的疾病，包括难治性个体的治疗。 （+）-1-（3,4-二氯苯基）-3-氮杂双环[3.1.0]己烷组合物被MAO-A或细胞色素P450酶中的任一或两者代谢，因此对患有细胞色素P450多态性或正在服用影响细胞色素P450途径的其他药物的个体进行治疗是有效的。
• NOVEL COMBINATIONS AND METHODS
  申请人：Euthymics Bioscience, Inc.

  公开号：US20150005359A1

  公开（公告）日：2015-01-01

  The present disclosure relates to novel methods of treating pain comprising administering to a human in need thereof an effective amount of (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, in free and/or pharmaceutically acceptable salt form, substantially free of the corresponding (−) enantiomer, wherein the human is a heavy drinker and/or binge drinker and/or wherein the human has compromised liver function and/or wherein the human is a codeine non-responder. The present disclosure also relates to a method of treating pain comprising concurrently or sequentially administering to a patient in need thereof an effective amount of (a) (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, in free and/or pharmaceutically acceptable salt form, and (b) acetaminophen. The present disclosure also relates to a method of treating pain comprising simultaneously or sequentially administering to a patient in need thereof an effective amount of (a) (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, in free and/or pharmaceutically acceptable salt form, and (b) a non-steroidal anti-inflammatory drug.
• US9566264B2
  申请人：——

  公开号：US9566264B2

  公开（公告）日：2017-02-14